Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792690 | 1.00 | ALDH1A1 (0.59) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL9549950 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL30430848 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL1771514 | 0.83 | CYP1A2 (0.63) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL29770446 | 0.81 | ALDH1A1 (0.59) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL4045859 | 0.81 | ALDH1A1 (0.59) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL9154966 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL9766051 | 0.79 | ALDH1A1 (0.62) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL8368811 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL23118890 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KDM4ECYP1A2CYP2C19TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018048930-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| CN-101747266-A | 4-substituted methyl-2(1H)-quinolinones compound and synthesis method thereof | DANDONG HENGYUE NEW MATERIAL C | 2010-06-23 | — | — | CN | claimed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| EP-4031547-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021055621-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055621-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| WO-2018048930-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| CN-101747266-A | 4-substituted methyl-2(1H)-quinolinones compound and synthesis method thereof | DANDONG HENGYUE NEW MATERIAL C | 2010-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885KDM4E 813/4885CYP1A2 2739/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885KDM4E 813/4885CYP1A2 2739/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885KDM4E 813/4885CYP1A2 2739/4885 |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885KDM4E 813/4885CYP1A2 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.